Abstract
My purpose in writing this paper is to explicate the current state of knowledge regarding estrogen replacement therapy when prescribed for prophylaxis of coronary heart disease in women. There is controversy in the literature surrounding the nature of estrogen replacement research, its findings, and the advisability of practitioners using these findings for practice. In this article this controversy is explored and recommendations for practice are made.